We assessed serum TGFBI levels in 427 patients admitted to surgical wards of the Second Affiliated Hospital of Zhejiang University and diagnosed with various malignant tumors: cholangiocarcinomas (n = 22), pancreatic carcinomas (n = 68), hepatic carcinomas (n = 47), lung carcinomas (n = 80), gastric carcinomas (n = 36), mammary carcinomas (n = 32), colon carcinomas (n = 62), brain carcinomas (n = 16), malignant lymphomas (n = 13), esophageal carcinomas (n = 15), prostate carcinomas (n = 10), and osteosarcomas (n = 26). This evidence concerns the gene TGFBI and lymphoma.